| Title: | Anabaseine Analogues as Modulators of Nicotinic Acetylcholine Receptor | ||
| Patent/Patent Application Number: | WO 2013/090260 A1 | Publication date: | June 20, 2013 |
| Priority Application: | US 2011–569539P | Priority date: | December 12, 2011 |
| Inventors: | Kem, W. R.; Soti, F.; Xing, H. | ||
| Assignee Company: | University of Florida Research Foundation, USA | ||
| Disease Area: | Nervous system diseases or disorders, inflammation, cancer | Biological Target: | Nicotinic Acetylcholine Receptor α7 (α7 nAChR) |
| Summary: | The patent application claims anabaseine derivatives as modulators of nicotinic acetylcholine receptor for the treatment of a variety of diseases including schizophrenia, Alzheimer’s disease, Pakinson’s disease, substance addiction, inflammation, and cancer | ||
| Important Compound Classes: |  |
||
| Key Structures: |  |
||
| Recent Review Articles: | Wallace T. L.; Bertrand D.. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin. Ther. Targets 2013, 17 (2), 139–155. | ||
| Biological Assays: | Binding affinities for the rat α7 nAChR and the rat α4β2 nAChR were determined using a ligand displacement assay. | ||
| Pharmacological Data: | Ligand displacement assay data for rat brain nAChRs
|
||
The authors declare no competing financial interest.